Skip to main content
Premium Trial:

Request an Annual Quote

Horizon Diagnostics, EMQN Ink Deal for Cell Line Reference Standards

NEW YORK (GenomeWeb News) – Horizon Diagnostics will provide genetically defined human cell line reference standards for distribution to molecular diagnostic laboratories worldwide under a deal with the European Molecular Genetics Quality Network (EMQN) announced today.

The cell line references will be distributed as part of EMQN's annual external quality assessment schemes to ensure sensitivity and reproducibility of diagnostic assays.

Horizon Diagnostics, a division of Horizon Discovery, will provide materials that contain known frequencies of mutations that currently guide the prescription of oncology therapies, particularly for melanoma, colon cancer, and lung cancer. Horizon will distribute the materials to participants of EMQN's proficiency testing schemes.

"Quality assurance schemes such as those organized by EMQN are essential to ensure that patients receive the correct treatment regimen based on their tumor mutation status," Paul Morrill, commercial director for Horizon Discovery, said in a statement. "Horizon’s technology offers pathologists and biologists an unprecedented level of control, and a resource for benchmarking the performance of assays against validated empirical reference standards. This is an invaluable component of patient care."

Financial and other terms of the deal were not disclosed.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.